Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity.
10.7499/j.issn.1008-8830.2203134
- Author:
Jiang-Biao XIE
1
;
Xin-Zhu LIN
1
Author Information
1. Department of Neonatology, Xiamen Maternal and Child Health Care Hospital, Xiamen, Fujian 361001, China.
- Publication Type:Review
- Keywords:
Apnea of prematurity;
Caffeine;
Gene polymorphism;
Preterm infant
- MeSH:
Apnea/genetics*;
Caffeine/therapeutic use*;
Humans;
Infant;
Infant, Newborn;
Infant, Newborn, Diseases;
Infant, Premature;
Infant, Premature, Diseases;
Polymorphism, Single Nucleotide
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(7):832-837
- CountryChina
- Language:Chinese
-
Abstract:
Apnea of prematurity (AOP) is one of the common diseases in preterm infants. The main cause of AOP is immature development of the respiratory control center. If AOP is not treated timely and effectively, it will lead to respiratory failure, hypoxic brain injury, and even death in severe cases. Caffeine is the first choice for the treatment of AOP, but its effectiveness varies in preterm infants. With the deepening of AOP research, more and more genetic factors have been confirmed to play important roles in the pathogenesis and treatment of AOP; in particular, the influence of single nucleotide polymorphism on the efficacy of caffeine has become a research hotspot in recent years. This article reviews the gene polymorphisms that affect the efficacy of caffeine, in order to provide a reference for individualized caffeine therapy. Citation.
